



# Godavari Biorefineries Limited

Investor Presentation | Q1 FY26

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Godavari Biorefineries Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale.

All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



## Q1 FY26 Performance

## Bio-based Chemicals Gain Traction in Green Transition

The **global chemicals industry** is seeing renewed momentum as companies accelerate the shift from **fossil-based to bio-based chemicals**. Global players are actively collaborating to **co-develop** and **create sustainable chemical solutions** as part of the ongoing **transition to bio-based alternatives**.

## Ethanol Blending Program

- According to ISMA - India has achieved its target of 20% ethanol blending with petrol five years ahead of schedule
- **Union Minister Nitin Gadkari** recently announced that **guidelines for 27% ethanol blending** will be introduced by **end-August**—the sector is poised for its next capex cycle amid rising blending targets and policy support.

## Balanced Ethanol Production

**ISMA** has urged the government to reinstate a **balanced 50:50 ratio** between **grain-based** and **sugar-based ethanol production** to help sugar mills diversify revenues, improve cash flows, and ensure timely farmer payments.

## Sugarcane Yield & Sugar Production

**India's sugar output** is projected to rise **15% YoY** to **35 million tonnes** in **Sugar Season 2025–26**, driven by an **above-average monsoon** boosting cane acreage and yields in key states like Maharashtra and Karnataka. The **FRP hike to ₹355/quintal** is incentivizing farmers to expand cultivation, while better **water availability** is expected to **enhance recovery rates and crushing volumes**.

## Government to Examine Sugar & Ethanol Price Revisions

Government has stated that it will examine pending demands related to increasing the **Minimum Selling Price (MSP)** of sugar and the **procurement price of ethanol** by oil companies in the **Group of Ministers (GoM)**.

# Key Revenue & EBITDA Growth Drivers

## Global - Transition to Green Chemistry



### Bio-Based Chemicals



Increase Bio-Based Specialty Chemicals Business



Increase proportion of Specialty Chemicals in portfolio

## India- Green Energy Transition



### Ethanol



Increase Capacity and Capacity Utilization



Diversify feedstock by adding Grain/Maize bolt-on Capacity

## Accelerating Growth with Operational Excellence and Strategic Investments



### Bio-based Specialty Chemicals

Focus on **expanding capacity** and implementing **debottlenecking initiatives in bio-based specialty chemicals** to drive long-term growth.



### Expanding Ethanol Capacity

- Our **200 KLPD fungible Grain/Maize distillery** is progressing ahead of schedule.
- Will add **60 Mn liters Ethanol Capacity** Per Annum
- **Commercial production** to be commenced by **end of CY25**
- Enhancing **operational flexibility** and supporting the **ethanol blending initiative**.

## Drug Discovery for Triple-Negative Breast Cancer (Promising preclinical efficacy in breast and prostate cancer)

### R&D Milestone- Drug Discovery efforts

#### Patent Update

- ❑ European patent for our novel anti-cancer molecule has been **validated in Spain, the United Kingdom, and as a Unitary Patent** covering multiple EU member states. Safety trials for the same molecule have been concluded without any **dose limiting toxicity (DLT)**
- ❑ Granted a patent by the China National Intellectual Property Administration (CNIPA) for another novel anti-cancer molecule – HYDROXY-1,4-NAPHTHALENEDIONE, demonstrated strong inhibitory effects on cancer and cancer stem cells in vitro

#### Safety Trials

- ❑ Safety trials have been concluded without any **dose limiting toxicity (DLT)**

#### Science

- ❑ Mechanism of Action **Established**



## Milestones

1 Pre-clinical trials



2 Safety trials



3 Mechanism of action



4 Preliminary Efficacy trials

5 Out-licensing of molecule

# Q1 FY26 Performance Highlights (Y-o-Y Basis)

(Consolidated)

Total Income

Rs. 534.0 Crs

+ 2% YoY

EBITDA

Rs. 6.5 Crs


Margin 1.2%

PAT


Rs. (16.0) Crs

Margin (3%)

EBITDA (Rs. Crs)




PBT (Rs. Crs)



EBITDA and PBT margins improved in Q1FY26 due to the restoration of the Ethanol Blending Program, debottlenecking in Specialty Chemicals and reduced finance costs



Finance Cost (Rs. Crs)



₹240 crore term debt repaid through IPO proceeds, leading to a significant reduction in finance costs

# Q1 FY26 Performance Highlights (Y-o-Y Basis)

(Consolidated)



■ Sugar & Cogen ■ Chemical ■ Ethanol ■ Unallocated

**Revenue from Bio-based chemicals & Ethanol increased to 65% in Q1FY26 compared to 54% in Q1FY25**

# Segmental Highlights-Bio-based Chemicals


(Consolidated)

Revenue (Rs. Crs)


Q1 FY25	Q1 FY26	YoY Growth
146.0	141.2	(3%)

Accelerating Growth Through Specialty Chemicals

Revenue Break-up



EBITDA (Rs. Crs)



Increased focus on high-margin specialty chemicals is expected to drive sustainable growth and strengthen overall profitability


(Consolidated)

Revenue (Rs. Crs)


Q1 FY25	Q1 FY26	YoY Growth
136.4	205.4	51%

*Gaining Traction in Ethanol Business*

Revenue (Rs. Crs)



EBITDA (Rs. Crs)



*B-heavy molasses-based Ethanol back in play after prolonged pause, poised for potential upside*


# Segmental Highlights- Sugar & Co-Generation

(Consolidated)


Revenue (Rs. Crs)

Q1 FY25	Q1 FY26	YoY Growth
234.4	177.5	(24%)

Revenue Break-up (%)



EBITDA (Rs. Crs)




# Consolidated Profit & Loss Statement – Q1 FY26

Particulars (in INR Cr)	Q1 FY26	Q1 FY25	Q4 FY25	FY25
<b>Revenue from Operations</b>	<b>533.2</b>	<b>522.5</b>	<b>579.5</b>	<b>1,870.3</b>
Other Income	0.7	2.7	9.3	16.7
<b>Total Income</b>	<b>534.0</b>	<b>525.3</b>	<b>588.8</b>	<b>1,886.9</b>
Cost of Materials Consumed	205.5	128.3	575.3	1,242.8
Purchase of Finished Goods	8.4	5.2	4.7	17.8
Changes in Inventories of Finished Goods and WIP	217.7	317.9	(222.5)	124.6
<b>Gross Profit</b>	<b>102.4</b>	<b>73.8</b>	<b>231.2</b>	<b>501.8</b>
<b>GP %</b>	<b>19.2%</b>	<b>14.1%</b>	<b>39.3%</b>	<b>26.6%</b>
Employee Benefits Expense	32.2	30.4	34.9	125.4
Other Expenses	63.8	52.9	74.6	256.1
<b>EBITDA*</b>	<b>6.5</b>	<b>(9.5)</b>	<b>121.7</b>	<b>120.3</b>
<b>EBITDA %</b>	<b>1.2%</b>	<b>(1.8%)</b>	<b>20.7%</b>	<b>6.4%</b>
Depreciation and Amortisation Expense	13.5	12.6	12.8	50.1
<b>EBIT</b>	<b>(7.0)</b>	<b>(22.1)</b>	<b>108.8</b>	<b>70.2</b>
Finance Costs	15.3	19.6	13.1	71.8
<b>PBT</b>	<b>(22.3)</b>	<b>(41.6)</b>	<b>95.7</b>	<b>(1.5)</b>
Tax Expense	(6.3)	(15.5)	23.8	(2.6)
<b>Profit/(Loss) after Tax excl. one time impact of Deferred Tax</b>	<b>(16.0)</b>	<b>(26.1)</b>	<b>71.9</b>	<b>1.1</b>
<b>PAT % (excl. one time impact of Deferred Tax)</b>	<b>(3.0%)</b>	<b>(5.0%)</b>	<b>12.2%</b>	<b>0.1%</b>
One time impact of Deferred Tax	0.0	0.0	0.0	24.5
<b>Profit/(Loss) after Tax incl. one time impact of Deferred Tax</b>	<b>(16.0)</b>	<b>(26.1)</b>	<b>71.9</b>	<b>(23.4)</b>
<b>PAT % (incl. one time impact of Deferred Tax)</b>	<b>(3.0%)</b>	<b>(5.0%)</b>	<b>12.2%</b>	<b>(1.2%)</b>

\* EBITDA Includes Other Income

# FY29 Outlook: Strategic Levers for Value Creation

## Unlocking 3X EBITDA by FY29 from FY25



\* Investment for current 200 KLPD fungible grain/maize distillery project is funded under interest subvention loan by Govt. Investments includes for bio-based specialty chemicals and ethanol. It is based on current prices

# Growth in Bio Based Chemicals & Ethanol

## Bio Based Chemicals

Major growth in the revenue from Bio-based Chemicals business would reflect in FY27,FY28 and FY29

## Ethanol

Major growth in the revenue from Ethanol business would reflect in FY26,FY27 and FY28

## Sugar & Cogeneration

Sugar and Co-generation business estimated "AS IS"

## Drug Discovery Molecule

The potential of out-licensing of Novel anti-cancer molecules not factored.



## Company Overview


# Integrated Bio-refinery across value chain: Sugar, Ethanol, Bio-Chemicals, Power & Others...

Planned Products

GRAIN BASED ETHANOL

SPECIALTY CHEMICALS

Current Products



Promoter has played a significant role in the development and growth of the company...



**Shri Samir Shantilal Somaiya** (Chairman & Managing Director)

- Conferred with the 'Knight of the Order of the Star of Italy'
- Conferred with 'Lala Shriram National Award for Leadership in the Chemical Industry' by the Indian Institute of Chemical Engineers (2022), and various awards including the Annual Chapter Award for Scholastic by the American Institute of Chemical Engineer in 1988 and the Student Award Certificate by the American Institute of Chemists Foundation in 1990.
- Bachelors' degree in science from Cornell University, a masters' degree in chemical engineering and a masters' degree in business administration from Cornell University, and a masters' degree in public administration from Harvard University

...supported by a well experienced board



**Dr. Sangeeta Arunkumar Srivastava**  
(Executive Director)

- Doctor of Philosophy degree ( PhD) in chemistry from Mumbai University
- Over 30 years of experience in R&D.



**Dr. Raman Ramachandran**  
(Non-Executive Director)

- Master's degree of science in entomology from Indian Agricultural Research Institute
- Former Head of BASF South Asia, CMD of BASF India Ltd, Ex MD & CEO of PI Industries, Dean, Faculty of Management at Somaiya Vidyavihar University.



**Kumar L Desai**  
(Independent Director)

- Bachelors' degree of law from University of Mumbai with 47+ years of experience as a practicing advocate
- Has been enrolled with the Bar Council of Maharashtra & Goa as an advocate since Sep 30, 1977.



**Bhalachandra Raghavendra Bakshi**  
(Executive Director)

- Bachelors' degree in science in agriculture
- Over 13 years of experience with GBL.



**Hemant Luthra**  
(Independent Director)

- Bachelors' degree of technology in Mechanical Engineering from IIT, Delhi
- Founder Chairman of Mahindra CIE, Mahindra Engineering Services, Mahindra Aerospace & Chairman of Mahindra Sanyo Steel.



**Sanjay Puri**  
(Independent Director)

- Masters of Management degree from Northwestern University & has 29+ years of experience in finance
- Associated with International Finance Corporation as the chief investment officer.



**Suhas Uttam Godage**  
(Executive Director (Works – Sakarwadi))

- Post graduate diploma in industrial fermentation & alcohol technology
- 26+ years of experience in chemicals industry and 15+ years of experience with GBL.



**Prof. Lakshmi Kantam Mannepilli**  
(Independent Director)

- Doctor of Philosophy degree ( PhD) in chemistry from Kurukshetra University
- Adjunct Professor at Tezpur University, Distinguished Professor at ICT Mumbai, former Director of CSIR-IICT, and ex-Board member at IIT Hyderabad; Fellow of INSA, NASI, and the Royal Society of Chemistry.



**Nitin Mehta**  
(Independent Director)

- Post graduate Diploma in Management from Management Development Institute, Gurgaon
- Vice President (Profit Center Head - Pasta) at Olam International, Nigeria. Prior to this, served as MD at L'Oreal Bangladesh.

# Thank You



Godavari Biorefineries Ltd  
CIN: L67120MH1956PLC009707  
Name – Mr. Ashish Sinha  
Title – AGM- IR & Finance  
Email – [investorrelations@somaiya.com](mailto:investorrelations@somaiya.com)



Ms. Prachi Ambre  
+91 83559 85370  
[Prachi.ambre@in.mpms.mufg.com](mailto:Prachi.ambre@in.mpms.mufg.com)

Mr. Irfan Raeen  
+91 97737 78669  
[irfan.raeen@in.mpms.mufg.com](mailto:irfan.raeen@in.mpms.mufg.com)

